The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age ...

In the U.S., respiratory syncytial virus (RSV) is responsible for up to 160,000 hospitalizations and 10,000 deaths annually among adults aged 65 and older.

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

By Dr. Liji Thomas, MD New data from six European countries reveals the true toll of respiratory syncytial virus on older ...

RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...